Antonio Matera

Dr. Antonio Matera

Università degli Studi di Milano, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FMFrancesco Maura
Francesco Maura
PBP. Leif Bergsagel
P. Leif Bergsagel
BZBachisio Ziccheddu
Bachisio Ziccheddu
SKShaji Kumar
Shaji Kumar
KMKylee Maclachlan
Kylee Maclachlan
SRS. Vincent Rajkumar
S. Vincent Rajkumar
Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). While these precursor conditions are asymptomatic, they are not entirely benign and carry a lifelong risk of progression to MM. Unlike other cancers defined by pathology, malignant transformation from MGUS or SMM to MM has so far relied on demonstration of clinical end-organ damage as morphology and cytogenetics cannot reliably distinguish them. In this study, using genomic data from 374 patients with MGUS or SMM (277 training, 97 validation), to our knowledge, we demonstrate for the first time the ability to identify malignant transformation in MGUS and SMM. We introduce the concept of genomic MM and genomic MGUS to differentiate the subsets of MGUS and SMM that are biologically malignant with genomic features indistinguishable from MM from the subset that is premalignant and unlikely to progress to malignancy. Importantly, we find that most SMM has biological features of malignant transformation indistinguishable from MM. As expected, this subset that we consider having genomic MM is associated with a high risk of progression to MM although some patients remained progression-free beyond 5 years. Conversely, 60% of MGUS and 10% of SMM have no evidence of malignant transformation (genomic MGUS), with no progression during follow-up. Integration of genomic features with the 2/20/20 International Myeloma Working Group model significantly improved the prediction of progression among genomic MM. These findings support the use of genomic criteria to refine the classification and the risk stratification in myeloma precursor conditions.

Verified
Journal Article
Open access
PDF file
Antonio MateraAntonio Matera
Antonio Matera
AMAlessio Marella
Alessio Marella
AMAkihiro Maeda
Akihiro Maeda
MVMatteo C. Da Vià
Matteo C. Da Vià
FLFrancesca Lazzaroni
Francesca Lazzaroni
MLMarta Lionetti
Marta Lionetti
Multiple myeloma (MM) has a highly heterogeneous genetic background, which complicates its molecular tracking over time. Nevertheless, each MM patient’s malignant plasma cells (PCs) share unique V(D)J rearranged sequences at immunoglobulin loci, which represent ideal disease biomarkers. Because the tumor-specific V(D)J sequence is highly expressed in bulk RNA in MM patients, we wondered whether it can be identified by single-cell RNA sequencing (scRNA-seq). To this end we analyzed CD138+ cells purified from bone marrow aspirates of 19 samples with PC dyscrasias by both a standard method based on bulk DNA and by an implementation of the standard 10x Genomics protocol to detect expressed V(D)J sequences. A dominant clonotype was easily identified in each sample, accounting on average for 83.65% of V(D)J-rearranged cells. Compared with standard methods, scRNA-seq analysis proved highly concordant and even more effective in identifying clonal productive rearrangements, by-passing limitations related to the misannealing of consensus primers in hypermutated regions. We next validated its accuracy to track 5 clonal cells with absolute sensitivity in a virtual sample containing 3180 polyclonal cells. This shows that single-cell V(D)J analysis may be used to find rare clonal cells, laying the foundations for functional single-cell dissection of minimal residual disease.

9 April 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
MVMatteo Claudio Da Vià
Matteo Claudio Da Vià
MLMarta Lionetti
Marta Lionetti
AMAlessio Marella
Alessio Marella
Antonio MateraAntonio Matera
Antonio Matera
ETErica Travaglino
Erica Travaglino
NBNiccolò Bolli
Niccolò Bolli
Monoclonal gammopathy of undetermined significance (MGUS) and clonal hematopoiesis (CH) are 2 preclinical clonal expansions of hematopoietic cells whose prevalence rises with age, reaching almost 10% in people of aged 70 years and older. The increased risk of myeloid malignancies in patients with myeloma is well defined, and the study of the association between CH and MGUS could help explain this phenomenon. Here, we analyzed a fully clinically annotated dataset of 777 older subjects (median age, 91 years) previously screened for prevalence of CH. The prevalence of MGUS and CH was 9.6% and 17.3%, respectively. We detected CH in 9.7% of the patients with MGUS and MGUS in 5.5% of the patients with CH. We did not find a significant correlation between the presence of MGUS and CH. Furthermore, the 2 conditions showed a differential association with clinical and laboratory covariates, suggesting that MGUS and CH may represent age-associated unrelated clonal drifts of hematopoietic cells. Confirmatory studies are needed to assess the relevance of CH in plasma cell disorders. This trial was registered at www.clinicaltrials.gov as #NCT03907553.

13 October 2026 in HemaSphere
Verified
Journal Article
Open access
AMAlfredo Marchetti
Alfredo Marchetti
FLFrancesca Lazzaroni
Francesca Lazzaroni
MVMatteo Claudio Da Via'
Matteo Claudio Da Via'
MLMarta Lionetti
Marta Lionetti
GMGiulia Maggioni
Giulia Maggioni
NBNiccolò Bolli
Niccolò Bolli
Hypomethylating agents (HMAs) combined with Venetoclax have reshaped the therapeutic landscape of acute myeloid leukemia (AML), yet the biological determinants of response remain unclear. We integrated clinical and genomic profiling in 132 newly diagnosed or relapsed/refractory AML patients treated with HMA‐Venetoclax and performed single‐cell RNA sequencing and T cell receptor (TCR) profiling in 10 newly diagnosed cases to define cellular and immune correlates of response. Response rates and survival aligned with published data. DNA Sequencing confirmed the favorable impact of IDH2 and the poor prognosis of TP53 mutations. scRNA‐seq and TCR analysis showed that responders exhibited expansion of cytotoxic CD8 + T cells, increased TCR clonal diversity, and activation of antigen‐presentation pathways. Nonresponders displayed baseline inflammatory signaling, impaired myeloid maturation, and a suppressive microenvironment enriched in IDO1 + dendritic cells. Resistant AMLs showed stem‐like dedifferentiation and sustained EMT. LAG‐3 expression marked dysfunctional T cell states and emerged as a potential biomarker and therapeutic target.